Allient (ALNT) Competitors

Allient has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market. Comparatively, Vontier has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

Allient pays an annual dividend of $0.16 per share and has a dividend yield of 0.2%. Vontier pays an annual dividend of $0.10 per share and has a dividend yield of 0.3%. Allient pays out 11.2% of its earnings in the form of a dividend. Vontier pays out 3.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Vontier is clearly the better dividend stock, given its higher yield and lower payout ratio.

Allient currently has a consensus target price of $79.83, suggesting a potential downside of 7.82%. Vontier has a consensus target price of $41.89, suggesting a potential upside of 40.82%. Given Vontier's higher probable upside, analysts plainly believe Vontier is more favorable than Allient.

Vontier has a net margin of 13.37% compared to Allient's net margin of 4.25%. Vontier's return on equity of 37.88% beat Allient's return on equity.

In the previous week, Vontier had 4 more articles in the media than Allient. MarketBeat recorded 7 mentions for Vontier and 3 mentions for Allient. Allient's average media sentiment score of 1.10 beat Vontier's score of 0.84 indicating that Allient is being referred to more favorably in the media.

61.6% of Allient shares are held by institutional investors. Comparatively, 95.8% of Vontier shares are held by institutional investors. 15.0% of Allient shares are held by insiders. Comparatively, 1.1% of Vontier shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Vontier has higher revenue and earnings than Allient. Vontier is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.

Mirion Technologies presently has a consensus price target of $26.38, suggesting a potential upside of 66.89%. Allient has a consensus price target of $79.83, suggesting a potential downside of 7.82%. Given Mirion Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe Mirion Technologies is more favorable than Allient.

Mirion Technologies has higher revenue and earnings than Allient. Allient is trading at a lower price-to-earnings ratio than Mirion Technologies, indicating that it is currently the more affordable of the two stocks.

Mirion Technologies has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Allient has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

78.5% of Mirion Technologies shares are owned by institutional investors. Comparatively, 61.6% of Allient shares are owned by institutional investors. 2.2% of Mirion Technologies shares are owned by insiders. Comparatively, 15.0% of Allient shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Mirion Technologies had 3 more articles in the media than Allient. MarketBeat recorded 6 mentions for Mirion Technologies and 3 mentions for Allient. Allient's average media sentiment score of 1.10 beat Mirion Technologies' score of 0.50 indicating that Allient is being referred to more favorably in the news media.

Allient has a net margin of 4.25% compared to Mirion Technologies' net margin of 2.56%. Allient's return on equity of 12.47% beat Mirion Technologies' return on equity.

61.6% of Allient shares are held by institutional investors. Comparatively, 69.7% of Aehr Test Systems shares are held by institutional investors. 15.0% of Allient shares are held by company insiders. Comparatively, 6.8% of Aehr Test Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Aehr Test Systems had 32 more articles in the media than Allient. MarketBeat recorded 35 mentions for Aehr Test Systems and 3 mentions for Allient. Allient's average media sentiment score of 1.10 beat Aehr Test Systems' score of 0.55 indicating that Allient is being referred to more favorably in the media.

Allient has higher revenue and earnings than Aehr Test Systems. Aehr Test Systems is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.

Allient currently has a consensus price target of $79.83, suggesting a potential downside of 7.82%. Aehr Test Systems has a consensus price target of $117.50, suggesting a potential upside of 51.89%. Given Aehr Test Systems' stronger consensus rating and higher probable upside, analysts plainly believe Aehr Test Systems is more favorable than Allient.

Allient has a net margin of 4.25% compared to Aehr Test Systems' net margin of -14.25%. Allient's return on equity of 12.47% beat Aehr Test Systems' return on equity.

Allient has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, Aehr Test Systems has a beta of 3.17, suggesting that its share price is 217% more volatile than the broader market.

61.6% of Allient shares are held by institutional investors. 15.0% of Allient shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Allient had 2 more articles in the media than Alamar Biosciences. MarketBeat recorded 3 mentions for Allient and 1 mentions for Alamar Biosciences. Allient's average media sentiment score of 1.10 beat Alamar Biosciences' score of 0.67 indicating that Allient is being referred to more favorably in the news media.

Allient has a net margin of 4.25% compared to Alamar Biosciences' net margin of 0.00%. Allient's return on equity of 12.47% beat Alamar Biosciences' return on equity.

Allient has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.

Alamar Biosciences currently has a consensus price target of $30.00, indicating a potential upside of 25.42%. Allient has a consensus price target of $79.83, indicating a potential downside of 7.82%. Given Alamar Biosciences' higher possible upside, analysts clearly believe Alamar Biosciences is more favorable than Allient.